• Explore /
  • Poster
  • / Phase 1b/2 study of combination <sup>177</sup>Lu girentuximab plus cabozantinib and nivolumab in treatment naïve patients with advanced clear cell RCC.

Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naïve patients with advanced clear cell RCC.

Abstract Poster

Authors

Elshad Hasanov

Elshad Hasanov

University of Texas MD Anderson Cancer Center, Houston, TX

Elshad Hasanov , Lesley Flynt , Rebecca Slack Tidwell , Hyunsoo Hwang , Roserika Brooks , Lauren Michelle Wood , Travis Solley , Dahlia Mack , Yuko Yamamura , Aradhana M. Venkatesan , Eric Jonasch

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS4605)

DOI

10.1200/JCO.2023.41.16_suppl.TPS4605

Abstract #

TPS4605

Poster Bd #

95a

Abstract Disclosures

Similar Posters

First Author: Elshad Hasanov

First Author: Elshad Hasanov

First Author: Pratik Rane

First Author: Thomas Powles